Common stock: Par value $.001
- Symbol
- RNTX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Rein Therapeutics, Inc.
RNTXNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On July 20, 2026, Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, for the purposes of: Electing two Class III directors to serve on our Board of Directors until our 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified;…
Company context
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications. Our lead product candidate is LTI-03, a peptide for which we conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis that has demonstrated the ability in both preclinical studies and clinical trials to protect healthy lung epithelial cells and reduce pro-fibrotic signaling. Our second product candidate is LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion patients, an indication that has no approved drug treatment. In June 2024, we decided to temporarily delay clinical development of LTI-01 in an effort to focus our resources on clinical development of LTI-03 and until additional funds are raised. In the fourth quarter of 2025, we decided to pause development activities related to LTI-01, preclinical programs targeting cystic fibrosis and a peptide program focused on the Cav1 protein for an indefinite period.
Current securities
Historical securities (1)
Recent company filings
- Regulation FD DisclosureSep 4, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingAug 27, 2026
- SCHEDULE 13G/A - filed by Lynwood Capital Management Inc. regarding Rein Therapeutics, Inc.Aug 14, 2026
- 10-Q filingAug 14, 2026
- SCHEDULE 13G/A - filed by Voss Capital, LP regarding Rein Therapeutics, Inc.Jul 14, 2026
Registered securities in this filing
REIN THERAPEUTICS, INC. · 8-K · Filed 2026-07-21
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders
On July 20, 2026, Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, for the purposes of:
Electing two Class III directors to serve on our Board of Directors until our 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified;
Approving an amendment to our restated certificate of incorporation to increase the number of authorized shares of common stock from 100 million shares to 200 million shares;
Ratifying the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the year ending December 31, 2026; and
───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Approving, on an advisory basis, the compensation of our named executive officers disclosed in the Proxy Statement.
Our stockholders elected two Class III directors, namely Josef H. von Rickenbach and Reinhard J. Ambros, Ph. D., with shares voted as follows:
Name For Withheld Broker
Non-Votes
─────────────────────────────────────────────────────────────────────────────
Josef H. von Rickenbach 25,402,442 13,202,963 25,098,629
Reinhard J. Ambros, Ph. D 25,404,238 13,201,167 25,098,629
In addition, our stockholders approved an amendment to our restated certificate of incorporation to increase the number of authorized shares of common stock from 100 million shares to 200 million shares, with shares voted as follows:
For 61,004,221
Against 2,394,208
Abstain 305,605
There were no broker non-votes on the approval of the above amendment to our restated certificate of incorporation.
In addition, our stockholders ratified the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the year ending December 31, 2026, with shares voted as follows:
For 62,953,351
Against 172,420
Abstain 578,263
There were no broker non-votes on the ratification of our independent registered public accounting firm.
In addition, our stockholders approved, on an advisory basis, the compensation of our named executive officers disclosed in the Proxy Statement, with shares voted as follows:
For 37,628,483
Against 914,331
Abstain 62,591
There were 25,098,629 broker non-votes on the approval, on an advisory basis, of the compensation of our named executive officers.